ライフサイエンスコーパス: rhabdoid tumor

1 (e.g., lung, synovial sarcoma, leukemia, and rhabdoid tumors).

2 e Beckwith-Wiedemann syndrome patients and a rhabdoid tumor.

3 cal features and molecular profiles of human rhabdoid tumors.

4 ly undefined genomic rearrangements in human rhabdoid tumors.

5 plex, is inactivated in nearly all pediatric rhabdoid tumors.

6 1 hepatocellular carcinoma, and 2 malignant rhabdoid tumors.

7 uppressor in familial and sporadic malignant rhabdoid tumors.

8 of childhood solid tumors, including lethal rhabdoid tumors.

9 WHO grade III), and seven atypical teratoid rhabdoid tumors.

10 rhabdoid tumors (MRTs) or atypical teratoid rhabdoid tumors.

11 nt a therapeutic target in atypical teratoid/rhabdoid tumors.

12 ly effective as novel therapeutic agents for rhabdoid tumors.

13 yclin D1 is a key mediator in the genesis of rhabdoid tumors.

14 osely resemble those of human Snf5-deficient rhabdoid tumors.

15 ed sarcoma (US), osteosarcoma, and malignant rhabdoid tumors.

16 toid tumor of the brain and three with renal rhabdoid tumors.

17 d in both rhabdoid cell lines and in primary rhabdoid tumors.

18 ir absence contributes to the progression of rhabdoid tumors.

19 per-enhancers, such as SOX2 in brain-derived rhabdoid tumors.

20 itive neuroectodermal tumor, ependymoma, and rhabdoid tumors, 5-year EFS rates were 32% +/- 5%, 17% +

21 g mutations of the SMARCB1 gene in malignant rhabdoid tumors, a highly aggressive childhood cancer.

22 driving roles first identified in malignant rhabdoid tumor, an aggressive pediatric cancer character

23 selected rare tumors (ie, atypical teratoid/rhabdoid tumor and CNS primitive neuroectodermal tumor).

24 SMARCB1 mutations predispose to rhabdoid tumors and schwannomas but the mechanisms under

25 an SWI/SNF complexes occur in most malignant rhabdoid tumors and some other malignancies.

26 n about the biology and clinical behavior of rhabdoid tumors and to begin to develop treatment strate

27 umor suppressor gene hSNF5/INI1 in malignant rhabdoid tumor, and the association of c-kit mutations w

28 epatoblastomas, 7 of 8 Wilms' tumors, 3 of 3 rhabdoid tumors, and 12 of 27 adenocarcinomas also teste

29 Rhabdoid tumors are aggressive pediatric malignancies fo

30 Rhabdoid tumors arise because of the loss of the tumor s

31 Malignant rhabdoid tumors arise in several anatomic locations and

32 Atypical teratoid/rhabdoid tumor (AT/RT) of the CNS is an extremely rare a

33 mors (sPNET) correspond to atypical teratoid/rhabdoid tumor (AT/RT), a rare childhood tumor.

34 t rhabdoid tumors, such as atypical teratoid/rhabdoid tumor (AT/RT).

35 these tumors are known as atypical teratoid/rhabdoid tumors (AT/RT).

36 ve pediatric atypical teratoid and malignant rhabdoid tumors (AT/RT).

37 Atypical teratoid/rhabdoid tumor (ATRT) is one of the most common brain tu

38 Atypical teratoid rhabdoid tumor (ATRT) of the CNS is a highly malignant n

39 lecular intertumor heterogeneity in teratoid/rhabdoid tumors (ATRTs) and extra-cranial MRTs (ecMRTs)

40 ecular inter-tumor heterogeneity in teratoid/rhabdoid tumors (ATRTs) and extra-cranial MRTs (ecMRTs)

41 We recently reported that atypical teratoid rhabdoid tumors (ATRTs) comprise at least two transcript

42 sociated with the poor prognosis seen in all rhabdoid tumors but only some RMS.

43 blastoma, glioblastoma and atypical teratoid rhabdoid tumor cell lines.

44 mediate PGBD5-induced DNA rearrangements in rhabdoid tumor cells.

45 distinguishable mutational landscapes, human rhabdoid tumors exhibit distinct enhancer H3K27ac signat

46 genetically engineered models for malignant rhabdoid tumors exist, none of them recapitulate AT/RT,

47 rs of the brain and 7 renal and 4 extrarenal rhabdoid tumors for mutations in the candidate rhabdoid

48 Here we sequenced the exomes of 35 rhabdoid tumors, highly aggressive cancers of early chil

49 the requirement of Cyclin D1 for genesis of rhabdoid tumors in vivo, we developed Ini1 heterozygous

50 gh a mechanism that is distinct from that of rhabdoid tumors in which SMARCB1 protein is completely a

51 identified in children with brain and renal rhabdoid tumors, indicating that INI1 is a tumor suppres

52 y INI1 and Cyclin D1 overexpression in human rhabdoid tumors is a common phenomenon.

53 ogeneity observed in patients with malignant rhabdoid tumors is unknown.

54 tumor (WT) share a similar genetic link with rhabdoid tumors, it was hypothesized that they may also

55 clear chromatin-remodeling factor SMARCB1 in rhabdoid tumors led to increased phosphorylation of eIF2

56 Malignant rhabdoid tumor (MRT) is an aggressive, highly lethal can

57 F5 function is usually observed in malignant rhabdoid tumor (MRT), a highly aggressive pediatric neop

58 Malignant rhabdoid tumors (MRT) are rare aggressive cancers that o

59 emodeling complex, is lost in most malignant rhabdoid tumors (MRT).

60 and a tumor suppressor mutated in malignant rhabdoid tumors (MRT).

61 Malignant rhabdoid tumors (MRTs) are rare lethal tumors of childho

62 mutations that result primarily in malignant rhabdoid tumors (MRTs) in humans and MRTs as well as oth

63 s extremely prevalent in pediatric malignant rhabdoid tumors (MRTs) or atypical teratoid rhabdoid tum

64 F5), which is inactivated in human malignant rhabdoid tumors (MRTs), interacts with GLI1.

65 astoma multiforme (n = 2), atypical teratoid/rhabdoid tumor (n = 1), malignant glioma (n = 1), and ch

66 n = 5), germinoma (n = 3), atypical teratoid rhabdoid tumor (n = 2), choroid plexus carcinoma (n = 2)

67 In atypical teratoid rhabdoid tumors, no correlation was found between cellul

68 study is to determine prognostic factors in rhabdoid tumor of the kidney (RTK), including both demog

69 The G401 cell line derived from a rhabdoid tumor of the kidney secretes the heparin-bindin

70 We examined 18 atypical teratoid and rhabdoid tumors of the brain and 7 renal and 4 extrarena

71 ygously or homozygously deleted in pediatric rhabdoid tumors of the brain, kidney and soft tissues.

72 INI1 is a tumor suppressor gene involved in rhabdoid tumors of the brain, kidney, and other extraren

73 A workshop on childhood atypical teratoid/rhabdoid tumors of the central nervous system, sponsored

74 predispose to two distinct tumor syndromes: rhabdoid tumor predisposition syndrome, with malignant p

75 enografts of WiT49 cells resembled malignant rhabdoid tumors rather than Wilms tumors.

76 inoma, medulloblastoma and atypical teratoid rhabdoid tumor) respond to JQ1 even when harboring genet

77 y and minimum tumor ADC in atypical teratoid rhabdoid tumors (rho = -0.786, P < .05).

78 Rhabdoid tumors (RT) are aggressive pediatric malignanci

79 Rhabdoid tumors (RTs) are aggressive and currently incur

80 Rhabdoid tumors (RTs) are rare, highly aggressive pediat

81 ially involved in the formation of malignant rhabdoid tumors, such as atypical teratoid/rhabdoid tumo

82 abdoid tumors for mutations in the candidate rhabdoid tumor suppressor gene, INI1.

83 on in 22q11, was identified as the candidate rhabdoid tumor suppressor gene.

84 e retained super-enhancers are essential for rhabdoid tumor survival, including some that are shared

85 ich SMARCB1 germline mutations predispose to rhabdoid tumors versus schwannomas are still unknown.

86 dels and show that early Smarcb1 loss causes rhabdoid tumors whereas loss at later stages combined wi

87 or stem cell transplant in the treatment of rhabdoid tumors will be published separately.

88 A series of primary rhabdoid tumors with chromosome 22q11 deletions were scr